Loading clinical trials...
Loading clinical trials...
Allogeneic Hematopoietic Stem Cell Transplantation Versus Autologous Hematopoietic Stem Cell Transplantation for Peripheral T-cell Lymphoma Patients With Partial Remission After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study(T-START-PR)
Conditions
Interventions
Autologous Hematopoietic Stem Cell Transplantation
Allogenic stem cell transplant (ASCT)
Locations
1
China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Start Date
December 31, 2025
Primary Completion Date
May 30, 2029
Completion Date
September 30, 2029
Last Updated
December 23, 2025
NCT07470996
NCT07389616
NCT07356245
NCT07353840
NCT04068597
NCT06072131
Lead Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions